Supplemental material
Journal of Dermatological Treatment
Volume 33, 2022 - Issue 3
Articles
Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice
S. Atalaya Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
https://orcid.org/0000-0002-9671-0386
https://orcid.org/0000-0002-9671-0386, J. M. P. A. van den Reeka Department of Dermatology, Radboud University Medical Center, Nijmegen, The NetherlandsCorrespondence[email protected]
https://orcid.org/0000-0002-3642-2673
https://orcid.org/0000-0002-3642-2673, J. M. M. Groenewoudb Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlandshttps://orcid.org/0000-0002-4974-150X
https://orcid.org/0000-0002-4974-150X, P. C. M. van de Kerkhofa Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlandshttps://orcid.org/0000-0003-0084-3131
https://orcid.org/0000-0003-0084-3131, W. Kievitb Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlandshttps://orcid.org/0000-0002-3984-1769
https://orcid.org/0000-0002-3984-1769 & E. M. G. J. de Jonga Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands;c Radboud University, Nijmegen, The Netherlandshttps://orcid.org/0000-0003-3872-5704
https://orcid.org/0000-0003-3872-5704